Related Experiment Videos
Should anaemia in subtypes of CRF patients be managed differently?
1Cliniques Universitaires St. Luc, Brussels, Belgium.
Insights
Epoetin therapy improves quality of life in cardiovascular disease patients by increasing hemoglobin. Dosing and target hemoglobin levels vary by condition, including diabetes, chronic renal failure, and sickle-cell anemia.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Anemia is common in various chronic diseases.
- Epoetin alfa is a key therapeutic agent for anemia.
- Optimal management strategies require specific patient population data.
Purpose of the Study:
- To review current evidence on epoetin therapy in diverse patient groups.
- To define optimal hemoglobin targets and dosing considerations.
- To identify knowledge gaps in epoetin's efficacy and safety.
Main Methods:
- Literature review of epoetin use in cardiovascular disease, diabetes, pediatrics, geriatrics, chronic renal failure (CRF), chronic obstructive pulmonary disease (COPD), sickle-cell anemia, and renal transplantation.
- Analysis of recommended hemoglobin levels and epoetin dosing.
- Evaluation of treatment outcomes and adverse events.
Main Results:
- Epoetin improves quality of life and exercise capacity in cardiovascular patients, reducing left ventricular hypertrophy.
- Recommended hemoglobin is 11-12 g/dl for cardiovascular disease, with slow titration in diabetics.
- Pediatric and adult epoetin needs are similar, though sensitivity differs; epoetin may delay pediatric CRF progression.
- Elderly patients benefit similarly to younger adults.
- For CRF and COPD, 11 g/dl is suggested.
- Sickle-cell anemia patients with CRF require 6-9 g/dl to prevent crises.
- Epoetin's long-term impact on renal transplant outcomes is unclear; higher doses may be needed post-transplant.
Conclusions:
- Epoetin therapy offers significant benefits across various patient populations with anemia.
- Individualized hemoglobin targets and careful dose titration are crucial.
- Further research is needed for specific conditions like CRF with COPD and post-transplant scenarios.
Abstract:
In patients with cardiovascular disease, partial correction of anaemia with epoetin improves quality of life and exercise capacity, and reduces left ventricular hypertrophy. The currently recommended haemoglobin in these patients is 11-12 g/dl. The optimal haemoglobin in patients with diabetes mellitus does not differ from that in non-diabetic patients; however, haemoglobin should be increased slowly. There is no difference in the recommended haemoglobin between children and adults. However, epoetin sensitivity is lower in children who, therefore, typically need the same absolute dose of epoetin as adults. Epoetin treatment may delay the progression of chronic renal failure (CRF) in paediatric patients. Elderly patients obtain similar benefits from epoetin as younger adults; moreover, there are no differences in the doses of epoetin required or the optimal haemoglobin. There are very few data available on the effects of epoetin in patients with CRF and chronic obstructive pulmonary disease. At present, a haemoglobin of 11 g/dl seems appropriate. In sickle-cell anaemia patients with CRF, a high haemoglobin could precipitate painful crises; consequently, the recommended haemoglobin is the pre-CRF concentration of 6-9 g/dl. There is no convincing evidence of any effect of previous epoetin treatment on the long-term outcome of renal transplantation. In patients with a failing or failed transplant, the required dose of epoetin may be higher than in pre-transplantation patients. In such cases, transplant nephrectomy might be considered.